William Blair reaffirmed their outperform rating on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) in a research note issued to investors on Wednesday,RTT News reports.
Separately, UBS Group lifted their price objective on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, January 27th.
View Our Latest Research Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Stock Up 2.4 %
About Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- Stock Analyst Ratings and Canadian Analyst Ratings
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- The Role Economic Reports Play in a Successful Investment Strategy
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Why Energy Transfer Belongs on Your Watchlist
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.
